Few phrases in a biotech filing carry as much weight, or as much misreading, as "substantial doubt about its ability to continue as a going concern." It is not editorializing and not a prediction of bankruptcy. It is a defined accounting disclosure, governed by a specific FASB standard, that management is required to make when the numbers cross a threshold. Reading it correctly means knowing what the standard asks, what the words mean, and what they do — and do not — say about a company's future.

The governing rule is FASB Accounting Standards Codification Topic 205-40, Presentation of Financial Statements — Going Concern. Under ASC 205-40, management has an affirmative responsibility, each reporting period, to evaluate whether conditions or events raise substantial doubt about the company's ability to meet its financial obligations as they become due within one year after the date the financial statements are issued. That one-year horizon is the heart of the test: "going concern" is not about solvency in the abstract, but about whether the company can fund the next twelve months. A real biotech 10-Q states both the standard and the conclusion.

"...history of significant losses, its negative cash flows from operations, its negative working capital, its limited liquidity resources currently on hand, and its dependence on substantial additional financing to fund its operations after the current resources are exhausted raise substantial doubt about its ability to continue to operate as a going concern within one year after the date that the Condensed Consolidated Financial Statements"— Sangamo Therapeutics, Inc., Form 10-Q (filed with the SEC), source

Notice how the disclosure is built. It names the conditions that triggered the doubt — significant losses, negative operating cash flow, negative working capital, limited liquidity, and dependence on additional financing — and ties them explicitly to the one-year window. In the same filing the company disclosed it "had cash and cash equivalents of $27.6 million" as of the period end. The structure is the standard at work: identify the specific conditions, measure them against obligations coming due within a year, and state whether substantial doubt exists. The language is required to be that specific because ASC 205-40 asks management to disclose the principal conditions, its evaluation, and its plans — not merely to assert a conclusion.

The two-step evaluation under ASC 205-40

ASC 205-40 prescribes the order of the analysis, and the order is what makes the disclosure meaningful. Step one: management evaluates whether the relevant conditions, considered in the aggregate, raise substantial doubt — and at this step it must not take into account the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued. In other words, a company cannot make the doubt disappear by pointing to a financing it merely hopes to complete. Step two: if substantial doubt exists, management then evaluates whether its plans sufficiently alleviate that doubt — but those mitigating plans count only if it is probable both that the plans will be effectively implemented and that, once implemented, they will mitigate the conditions, within the one-year window (and any plan relied upon must typically have board approval before the statements are issued).

That sequencing is why the disclosure is informative rather than boilerplate. The standard forces management to first state the hard conditions on a no-rescue basis, then separately address whether credible, probable plans close the gap. A filing that reports substantial doubt and concludes management's plans do not alleviate it is a materially different disclosure from one that reports doubt arose but probable plans alleviate it. Reading the going-concern footnote means reading both steps, not just the headline phrase.

What the disclosure does and does not mean

A going-concern disclosure signals dependence on future financing within twelve months; it is not a statement that the company is insolvent today or will fail. For clinical-stage biotech specifically, the pattern is structural: companies routinely run sustained operating losses while advancing programs that generate no revenue, so a thin cash balance against that burn can cross the ASC 205-40 threshold even for a company actively executing financings and deals. The disclosure tells the reader the company must raise capital, restructure, partner, or otherwise act within the year — and that, on a no-mitigation basis, current resources do not cover that period.

It also helps to separate the going-concern disclosure made by management from any going-concern emphasis raised by the independent auditor. ASC 205-40 places the primary evaluation and disclosure obligation on management, and it applies to interim filings such as the 10-Q, which is why substantial-doubt language can appear in a quarterly report and not only in an audited annual report. Separately, an auditor may include an explanatory paragraph about going concern in its report on the annual financial statements when substantial doubt exists — that auditor language travels with the 10-K, not the 10-Q. The two are related but distinct: management's ASC 205-40 assessment is a continuous, every-period responsibility, while the auditor's statement is an annual audit output. A reader who sees substantial-doubt language should note which one they are looking at, because they originate from different parties and attach to different filings, even though they describe the same underlying condition.

The reading discipline follows directly. When a 10-Q or 10-K contains "substantial doubt about its ability to continue as a going concern," locate the specific conditions management lists, note the cash figure and the one-year horizon, and then read management's plans and whether the filing concludes those plans alleviate the doubt. Pair it with the runway arithmetic — cash divided by burn — and the two disclosures corroborate each other: going concern is the formal, standard-defined version of the same question that runway answers numerically. Both live in the filing on sec.gov, and both are written to be checked against the company's own balance sheet.